Omada Health, Inc. (NASDAQ:OMDA – Get Free Report) CFO Steven Cook sold 6,800 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $17.23, for a total value of $117,164.00. Following the completion of the transaction, the chief financial officer owned 187,209 shares in the company, valued at approximately $3,225,611.07. The trade was a 3.50% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.
Omada Health Stock Down 1.4%
NASDAQ:OMDA traded down $0.24 on Tuesday, hitting $17.09. The stock had a trading volume of 729,778 shares, compared to its average volume of 1,213,043. The business’s fifty day moving average is $15.45 and its 200 day moving average is $14.80. The company has a market cap of $1.02 billion and a PE ratio of -63.30. Omada Health, Inc. has a 52 week low of $10.28 and a 52 week high of $26.92.
Omada Health (NASDAQ:OMDA – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.03. The firm had revenue of $78.05 million during the quarter. Omada Health had a negative return on equity of 1.82% and a negative net margin of 2.22%. Equities analysts predict that Omada Health, Inc. will post -0.01 earnings per share for the current fiscal year.
Institutional Trading of Omada Health
Analyst Ratings Changes
Several brokerages have recently commented on OMDA. Evercore reissued an “outperform” rating and issued a $20.00 price objective on shares of Omada Health in a research note on Friday, May 8th. Wells Fargo & Company increased their price objective on Omada Health from $17.00 to $18.00 and gave the stock an “equal weight” rating in a research note on Friday, May 8th. Citigroup reissued an “outperform” rating on shares of Omada Health in a research note on Friday, May 8th. The Goldman Sachs Group reissued a “buy” rating on shares of Omada Health in a research note on Friday, May 8th. Finally, BMO Capital Markets lowered their price objective on Omada Health from $27.00 to $18.00 and set an “outperform” rating for the company in a research note on Friday, March 6th. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $22.91.
Read Our Latest Report on OMDA
About Omada Health
Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.
In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.
See Also
- Five stocks we like better than Omada Health
- Gravity Check: Houston, SpaceX Has a Valuation Problem
- Strategy’s Bitcoin Rally Has a Hidden Engine
- Okta’s AI Moment May Be Bigger Than Investors Realize
- 3 Rate-Ready Stocks for the New Fed Chair’s First Big Test
Receive News & Ratings for Omada Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omada Health and related companies with MarketBeat.com's FREE daily email newsletter.
